<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The advantages of neoadjuvant chemotherapy are the ability to 1) increase the rate of breast conservation and improve operability, 2) to reduce mortality by recognizing resistance mechanisms early, and 3) to investigate the activity of new agents by assessing the pathological complete response rate as a surrogate marker for clinical efficacy </plain></SENT>
<SENT sid="1" pm="."><plain>The German Breast Group (GBG) is a cooperative study group which focuses on neoadjuvant therapy for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This group cooperates closely with the German Gynecological <z:hpo ids='HP_0002664'>Oncology</z:hpo> Working Group-Breast (AGO-B) </plain></SENT>
<SENT sid="3" pm="."><plain>Additionally, these two German study groups maintain close ties with other national and international study groups, such as the Breast International Group (BIG), Austrian Breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e> Study Group (ABCSG), Central European Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (CECOG), International Cooperative <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group (ICCG) and National Surgical Adjuvant Breast Project (NSABP) </plain></SENT>
<SENT sid="4" pm="."><plain>A series of clinical trials evaluating the role of neoadjuvant therapy in women with primary <z:hpo ids='HP_0003002'>breast cancer</z:hpo> have been designed, performed and published over the last 10 years </plain></SENT>
<SENT sid="5" pm="."><plain>This article summarizes the results of the neoadjuvant trials that have been conducted by the German study groups, outlines ongoing clinical research projects, and discusses concepts for future clinical trials </plain></SENT>
</text></document>